CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
•Kansas City, Kansas, United States and 60 other locations
binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...
Phase 3
•Westwood, Kansas, United States and 227 other locations
The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the com...
Phase 3
•Westwood, Kansas, United States and 55 other locations
and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...
Phase 3
•Kansas City, Kansas, United States and 58 other locations
lymphodepletion and interleukin-2, work for treating patients with melanoma that cannot be removed by surgery (unresectable) or that has spr...
Phase 2
•Kansas City, Kansas, United States
to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...
Phase 3
•Westwood, Kansas, United States and 183 other locations
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma...
Phase 1, Phase 2
•Westwood, Kansas, United States and 9 other locations
combined with nivolumab in patients with unresectable or metastatic melanoma. A separate open-label cohort of adults with new, progressive b...
Phase 3
•Kansas City, Missouri, United States and 138 other locations
treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 contai...
Phase 3
•Westwood, Kansas, United States and 29 other locations
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with a...
Phase 2
•Fairway, Kansas, United States and 8 other locations
Clinical trials
Research sites
Resources
Legal